Protara Therapeutics Inc.

News & Events

Press Releases

In The Media

1. Protara Therapeutics to Participate in Upcoming Investor Conferences

   GlobeNewswire MAY 13, 2025 8:00 AM EDT
   NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clini...
   READ ARTICLE

2. Protara Therapeutics Announces First Quarter 2025 Financial Results and Provides Business Update

   GlobeNewswire MAY 8, 2025 8:00 AM EDT
   Reported positive interim results demonstrating durable responses in the ongoing Phase 2 ADVANCED...
   READ ARTICLE

3. Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

   GlobeNewswire MAY 1, 2025 4:09 PM EDT
   NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA) (ȁ...
   READ ARTICLE

4. Protara Therapeutics Announces Positive Interim Results Demonstrating Durable Responses in the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC

   GlobeNewswire APR 26, 2025 10:00 AM EDT
   TARA-002 demonstrates 100% complete response rate at any time and 67% 12-month landmark complete ...
   READ ARTICLE

5. Protara Therapeutics to Host Conference Call and Webcast to Review Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Monday, April 28, 2025

   GlobeNewswire APR 23, 2025 8:00 AM EDT
   NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a cl...
   READ ARTICLE

6. Protara Therapeutics Announces Appointment of Leonardo Viana Nicacio, M.D., as Chief Medical Officer

   GlobeNewswire APR 15, 2025 4:13 PM EDT
   NEW YORK, April 15, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a cli...
   READ ARTICLE

7. Protara Therapeutics to Present Interim Analysis from the Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the American Urological Association Annual Meeting

   GlobeNewswire APR 10, 2025 4:05 PM EDT
   NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a cli...
   READ ARTICLE

8. Protara Therapeutics Announces Encore Presentation of Results from THRIVE-1 Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support

   GlobeNewswire MAR 19, 2025 8:00 AM EDT
   Data to be featured during oral presentation at the American Society for Parenteral and Enteral N...
   READ ARTICLE

9. Protara Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

   GlobeNewswire MAR 5, 2025 8:00 AM EST
   Reported positive six-month data from ADVANCED-2 trial of TARA-002 in patients with NMIBC; Announ...
   READ ARTICLE

10. Protara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

    GlobeNewswire FEB 26, 2025 8:00 AM EST
    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clin...
    READ ARTICLE